-
EP4129297
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4129297
| EP4129297 - TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 11.08.2023 Database last updated on 28.06.2024 | |
| Former | The application has been published Status updated on 06.01.2023 | Most recent event Tooltip | 28.03.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states UWM Research Foundation, Inc. 1440 East North Avenue Milwaukee, WI 53202 / US | For all designated states Centre For Addiction And Mental Health 1001 Queen Street West Toronto, ON M6J 1H4 / CA | For all designated states University of Belgrade-Faculty of Pharmacy Vojvode Stepe 450 Belgrade 11221 / RS | [2023/06] | Inventor(s) | 01 /
COOK, James M. Milwaukee, 53217 / US | 02 /
LI, Guanguan Milwaukee, 53211 / US | 03 /
POE, Michael, Ming-Jin Kalamazoo, 49008 / US | 04 /
SAVIC, Miroslav M. 11000 Belgrade / RS | 05 /
SIBILLE, Etienne Toronto, M4Y 3G4 / CA | [2023/06] | Representative(s) | Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB | [2023/06] | Application number, filing date | 22181243.1 | 20.03.2017 | [2023/06] | Priority number, date | US201662310409P | 18.03.2016 Original published format: US 201662310409 P | [2023/06] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4129297 | Date: | 08.02.2023 | Language: | EN | [2023/06] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 16.12.2022 | Classification | IPC: | A61K31/5517, A61P25/18, C07F7/08, A61P25/24, A61P25/28, A61P25/00, // C07D487/04 | [2023/06] | CPC: |
C07D487/04 (EP,US);
A61P25/00 (EP);
A61P25/18 (EP);
A61P25/22 (US);
A61P25/24 (EP);
A61P25/28 (EP);
C07F7/0812 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/37] |
| Former [2023/06] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | BEHANDLUNG VON KOGNITIVEN UND STIMMUNGSSYMPTOMEN BEI NEURODEGENERATIVEN UND NEUROPSYCHIATRISCHEN ERKRANKUNGEN MIT ALPHA5-HALTIGEN GABAA-REZEPTORAGONISTEN | [2023/06] | English: | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | [2023/06] | French: | TRAITEMENT DE TROUBLES COGNITIFS ET DE SYMPTÔMES DE L'HUMEUR DANS DES TROUBLES NEURODÉGÉNÉRATIFS ET NEUROPSYCHIATRIQUES AVEC DES AGONISTES DU RÉCEPTEUR GABAA CONTENANT ALPHA5 | [2023/06] | Examination procedure | 07.08.2023 | Examination requested [2023/37] | 07.08.2023 | Date on which the examining division has become responsible | 01.09.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 09.11.2023 | Amendment by applicant (claims and/or description) | Parent application(s) Tooltip | EP17767701.0 / EP3439665 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 09.11.2023 | Request for further processing filed | 09.11.2023 | Full payment received (date of receipt of payment) Request granted | 20.11.2023 | Decision despatched | Fees paid | Renewal fee | 27.06.2022 | Renewal fee patent year 03 | 27.06.2022 | Renewal fee patent year 04 | 27.06.2022 | Renewal fee patent year 05 | 27.06.2022 | Renewal fee patent year 06 | 27.03.2023 | Renewal fee patent year 07 | 27.03.2024 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I] - NAMJOSHI OJAS A ET AL, "Search for [alpha]3[beta]2/3[gamma]2 subtype selective ligands that are stable on human liver microsomes", BIOORGANIC & MEDICINAL CHEMISTRY : A TETRAHEDRON PUBLICATION FOR THE RAPID DISSEMINATION OF FULL ORIGINAL RESEARCH PAPERS AND CRITICAL REVIEWS ON BIOMOLECULAR CHEMISTRY, MEDICINAL CHEMISTRY AND RELATED DISCIPLINES, (20121115), vol. 21, no. 1, doi:10.1016/J.BMC.2012.10.057, ISSN 0968-0896, pages 93 - 101, XP028961414 [I] 1-16 * abstract;; compounds 10-13 * DOI: http://dx.doi.org/10.1016/j.bmc.2012.10.057 | [A] - MARTA FILIZOLA ET AL, "Benzodiazepine-Induced Hyperphagia: Development and Assessment of a 3D Pharmacophore By Computational Methods", JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, US, (20000401), vol. 17, no. 5, doi:10.1080/07391102.2000.10506566, ISSN 0739-1102, pages 769 - 778, XP055628998 [A] 1-16 * page 5, compound 230384 * DOI: http://dx.doi.org/10.1080/07391102.2000.10506566 | [AP] - STAMENIC TAMARA TIMIC ET AL, "Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABAAreceptors containing the [alpha]5 subunit", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, (20160914), vol. 791, doi:10.1016/J.EJPHAR.2016.09.016, ISSN 0014-2999, pages 433 - 443, XP029805232 [AP] 1-16 * abstract, compound 1 * DOI: http://dx.doi.org/10.1016/j.ejphar.2016.09.016 | by applicant | US2011261711 | - GUILLOUX et al., Molecular Psychiatry, (20120000), vol. 17, pages 1130 - 1142 | - TRIPP et al., Am J Psychiatry, (20120000), vol. 169, pages 1194 - 1202 | - NORTHOFFSIBILLE, Molecular Psychiatry, (20140000), vol. 19, pages 966 - 977 | - PIANTODOSI et al., Frontiers in Pharmacology, (20160000), vol. 7, page 446 | - FISCHELL et al., Neuropsychopharmacology, (20150000), vol. 40, pages 2499 - 2509 | - LINSIBILLE, Frontiers Pharmacology, (20130000), vol. 4, page 110 | - WHITEMANITPISITKUL, Drug Met. Disp., (20010000), vol. 29, pages 957 - 66 | - SWINYARD, E. A et al., Comprehensive Organic Transformations, VCH Publishers, Inc., (19890000), pages 85 - 102 | - WHITE, H. S. et al., Ital J Neurol Sci, (19950000), vol. 16, pages 73 - 7 | - CHOUDHARY et al., Mol Pharmacol., (19920000), vol. 42, pages 627 - 33 | - SAVIC et al., Progress in Neuro-Psychopharmacology & Biological Psychiatry, (20100000), vol. 34, pages 376 - 386 | - FISHER et al., Mol Pharmacol, (19970000), vol. 52, pages 714 - 724 | - PIANTADOSI et al., Front Pharmacol, (20160000), vol. 7, page 446 | - GALLAGHER et al., Behav Neurosci, (19930000), vol. 107, pages 618 - 626 | - WILLIAMS, ILAR J, (20140000), vol. 55, pages 310 - 332 | - SCHWABE et al., Neurosci & Biobehavioral review, (20100000), vol. 34, pages 584 - 591 | - MORICI et al., Behav Brain Research, (20150000), vol. 292, pages 241 - 251 | - MILLANBALES, Neurosci & Biobehavioral Reviews, (20130000), vol. 37, pages 2166 - 2180 | - LALONDE, Neurosci & Biobehavioral Reviews, (20020000), vol. 26, pages 91 - 104 | - CAI et al., Bioanalysis, (20130000), vol. 5, pages 1691 - 701 | - CRYANMOMBEREAU, Molecular Psychiatry, (20040000), vol. 9, page 326 | - PHILLIPSLEDOUX, Behavioral Neuroscience, (19920000), vol. 106, pages 274 - 285 | - WILLNER, Neuropsychobiology, (20050000), vol. 52, pages 90 - 110 | - FISCHER et al., Neuropharmacology, (20100000), vol. 59, pages 612 - 618 | - PHAM et al., J Neurosci Methods, (20090000), vol. 178, pages 323 - 326 | - CRAWLEY, Neurosci Biobehav Rev, (19850000), vol. 9, pages 37 - 44 | - SAVIC et al., Int. J. Neuropsychopharmacol., (20090000), vol. 12, pages 1179 - 1193 | - DEACON, Nat Protocols, (20060000), vol. 1, page 122 | - KINSEY et al., Pharmacol Biochem Behav, (20110000), vol. 98, page 21 | - JANUS et al., Nature, (20000000), vol. 408, pages 979 - 982 | - GILL et al., Neuropsychopharmacology, (20110000), vol. 36, pages 1903 - 1911 | - TANG et al., Behavioral Brain Research, (20020000), vol. 136, pages 555 - 569 | - VOSS et al., European Journal of Pharmacology, (20030000), vol. 482, pages 215 - 222 | - WHITE, H. S. et al., Antiepileptic Drugs, Raven Press, (19950000), pages 99 - 110 | - SWINYARD et al., J. Physiol., (19610000), vol. 132 | - STAMENIC et al., Eur. J. Pharmacol., (20160000), vol. 791, pages 433 - 443 | - CHESTNUT et al., J. Immunol. Methods, (19960000), vol. 193, pages 17 - 27 | - OBRADOVIC et al., Brain Res, (20140000), vol. 1554, pages 36 - 48 | - CAS , no. 67-56-1 |